What are the indications, dosing regimens, and contraindications for Xeralto (rivaroxaban) in adults?

Xarelto (Rivaroxaban): Indications, Dosing, and Contraindications

Xarelto (rivaroxaban) is an oral direct factor Xa inhibitor with multiple FDA-approved indications requiring specific dosing regimens based on indication and patient characteristics, with absolute contraindications including active pathological bleeding and severe hypersensitivity. 1

FDA-Approved Indications

Rivaroxaban is approved for the following indications 1:

Stroke Prevention in Atrial Fibrillation

• Standard dose: 20 mg once daily with the evening meal 2
• Reduced dose: 15 mg once daily with the evening meal for patients with CrCl 15-50 mL/min 2
• Must be nonvalvular atrial fibrillation (not for use with mechanical valves or moderate-to-severe mitral stenosis) 2

Venous Thromboembolism (VTE) Treatment

• DVT/PE treatment: 15 mg twice daily with food for 21 days, then 20 mg once daily with food 3, 1
• Recurrence prevention: 10 mg once daily (with or without food) after completing at least 6 months of standard anticoagulation 4, 1

VTE Prophylaxis

• Post-orthopedic surgery: 10 mg once daily (with or without food) 5, 1
• Acutely ill medical patients: 10 mg once daily for 31-39 days total duration 1

Cardiovascular Disease

• CAD or PAD: 2.5 mg twice daily (with or without food) in combination with aspirin 75-100 mg once daily 1

Pediatric Indications

• VTE treatment and thromboprophylaxis post-Fontan procedure (weight-based dosing per prescribing information) 1

Critical Dosing Considerations

Renal Function Adjustments

For atrial fibrillation:

• CrCl >50 mL/min: 20 mg once daily
• CrCl 15-50 mL/min: 15 mg once daily
• CrCl <15 mL/min or dialysis: Not recommended due to lack of clinical trial data 2

For VTE treatment:

• Standard dosing can be used with CrCl ≥30 mL/min
• Avoid in severe renal impairment (CrCl <30 mL/min) 6, 1

Administration Requirements

Critical pitfall: The 15 mg and 20 mg tablets must be taken with food to ensure adequate absorption (80-100% bioavailability), while the 10 mg tablet can be taken with or without food 2, 1. The evening meal timing is specifically recommended for atrial fibrillation dosing 2.

Absolute Contraindications

Per FDA labeling 1:

1. Active pathological bleeding
2. Severe hypersensitivity reaction to rivaroxaban

Major Warnings and Precautions

Boxed Warnings 1

A. Premature Discontinuation Risk:

• Stopping rivaroxaban increases thrombotic event risk
• Consider bridging with another anticoagulant if discontinued for reasons other than bleeding or treatment completion

B. Spinal/Epidural Hematoma:

• Risk with neuraxial anesthesia or spinal puncture
• Can result in permanent paralysis
• Monitor frequently for neurological impairment

Additional High-Risk Situations

Avoid rivaroxaban in:

• End-stage renal disease or dialysis (insufficient evidence for AF indication) 2
• Severe hepatic impairment (Child-Pugh B or C) or hepatic disease with coagulopathy 1
• Prosthetic heart valves (not recommended) 1
• Triple-positive antiphospholipid syndrome (increased thrombosis risk) 1

Use with extreme caution in:

• Gastric or gastroesophageal tumors - significantly increased bleeding risk with rivaroxaban; LMWH preferred in cancer patients with GI malignancies 3
• Pregnancy - potential for obstetric hemorrhage 1

Drug Interactions

Avoid concomitant use with:

• Combined P-glycoprotein AND strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir, clarithromycin) 2, 1
• Combined P-glycoprotein AND strong CYP3A4 inducers (e.g., rifampin, phenytoin, carbamazepine) 2, 1
• Other anticoagulants (avoid combination therapy) 1

Increased bleeding risk with:

• NSAIDs and aspirin (particularly doses >100 mg) 7, 1
• Antiplatelet agents like clopidogrel 1

Common Pitfalls to Avoid

1. Underdosing in AF: Do not empirically reduce dose below guideline recommendations without meeting specific criteria - this increases stroke risk without improving safety 8

2. Food requirement confusion: Remember 15 mg and 20 mg tablets require food; 10 mg does not 2

3. Renal function monitoring: Must calculate CrCl (not just serum creatinine) to determine appropriate dosing 2

4. Cancer patients with GI malignancies: Rivaroxaban showed 2.9% higher absolute major bleeding rate versus dalteparin in the Hokusai VTE Cancer Study, confined to GI cancer patients 3

5. Transition protocols: When switching from/to other anticoagulants, follow specific timing protocols in prescribing information to avoid gaps or overlap 1

Monitoring

No routine coagulation monitoring required due to predictable pharmacokinetics 9, 10. However, monitor:

• Hemoglobin/hematocrit and platelets every 2-3 days for first 14 days, then every 2 weeks 3
• Renal function periodically, especially in elderly or those with baseline impairment 2
• Signs of bleeding or thrombosis clinically 1